Wenhao Zou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenhao Zou has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chengju Luo
Affiliated Hospital of Nantong University 1 Department of Pharmacy Pharmacy School of Nantong University, Nantong, China
11 shared publications - Fengliang Song
Affiliated Hospital of Nantong University 1 Department of Pharmacy Pharmacy School of Nantong University, Nantong, China
11 shared publications - Hui Yang
Affiliated Hospital of Nantong University 1 Department of Pharmacy Pharmacy School of Nantong University, Nantong, China
11 shared publications - Jiaxin Ye
Affiliated Hospital of Nantong University 1 Department of Pharmacy Pharmacy School of Nantong University, Nantong, China
11 shared publications - Lei Wang
Affiliated Hospital of Nantong University 4 Department of General Surgery , Nantong, China
11 shared publications - Qian Ding
School of Pharmacy, Macau University of Science and Technology, Macau SAR, China; Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China
11 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S2: Pseudotime analysis of hepatocyte differentiation and clinical correlation of ABHD6 with lenvatinib resistance.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S2: Pseudotime analysis of hepatocyte differentiation and clinical correlation of ABHD6 with lenvatinib resistance.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S3: Lenvatinib resistance induce functional validation of ABHD6 in HepG2 and Huh7 cell lines.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S3: Lenvatinib resistance induce functional validation of ABHD6 in HepG2 and Huh7 cell lines.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S1: Characterization of hepatocyte lineage identity, metabolic heterogeneity, and differentiation trajectories.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S1: Characterization of hepatocyte lineage identity, metabolic heterogeneity, and differentiation trajectories.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S6: Transcriptomic analysis of lenvatinib-resistant vs. sensitive Huh7 Cells.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S6: Transcriptomic analysis of lenvatinib-resistant vs. sensitive Huh7 Cells.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S4: Lenvatinib resistance induce functional validation of the catalytic-dead ABHD6 (S148A) mutant.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S4: Lenvatinib resistance induce functional validation of the catalytic-dead ABHD6 (S148A) mutant.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) frequently develops resistance to lenvatinib, a first-line tyrosine kinase inhibitor. Resistance arises from heterogeneous mechanisms involving metabolic reprogramming and mitochondrial adaptation, implicating regulators of these processes as potential therapeutic targets. In this study, we identified α/β hydrolase domain containing 6 (ABHD6) as a critical driver of lenvatinib resistance by perturbing mitochondrial dynamics. Ligand binding at the S148 catalytic site allosterically controlled a molecular switch between canonical enzymatic and noncanonical scaffolding functions of ABHD6, and the proresistance function was independent of catalysis but required an unoccupied catalytic site. In resistant HCC, the Warburg effect elevated lactate, leading to K245 lactylation of ABHD6. This modification triggered the mitochondrial translocation of ABHD6, in which it functioned as a scaffold that competitively bound the fission regulator mitochondrial fission 1 (FIS1) and displaced dynamin-related protein 1 (DRP1). Disruption of the fission machinery stabilized hyperfused mitochondria, thereby conferring lenvatinib resistance by suppressing drug-induced apoptosis and ROS generation. Both inhibiting lactate production and enforcing occupancy of the S148 site with substrates or a specific inhibitor blocked formation of the ABHD6–FIS1 complex, reactivated mitochondrial fission, and restored lenvatinib sensitivity. This study identified a lactate-driven functional switch in ABHD6 and established that targeting this allosteric mechanism is an effective therapeutic strategy to overcome lenvatinib resistance.Significance:Lactylated ABHD6 moonlights as a regulator of mitochondrial dynamics by sequestering FIS1 to drive lenvatinib resistance in hepatocellular carcinoma, which can be overcome by targeting ABHD6 to disrupt the non-canonical scaffolding function.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) frequently develops resistance to lenvatinib, a first-line tyrosine kinase inhibitor. Resistance arises from heterogeneous mechanisms involving metabolic reprogramming and mitochondrial adaptation, implicating regulators of these processes as potential therapeutic targets. In this study, we identified α/β hydrolase domain containing 6 (ABHD6) as a critical driver of lenvatinib resistance by perturbing mitochondrial dynamics. Ligand binding at the S148 catalytic site allosterically controlled a molecular switch between canonical enzymatic and noncanonical scaffolding functions of ABHD6, and the proresistance function was independent of catalysis but required an unoccupied catalytic site. In resistant HCC, the Warburg effect elevated lactate, leading to K245 lactylation of ABHD6. This modification triggered the mitochondrial translocation of ABHD6, in which it functioned as a scaffold that competitively bound the fission regulator mitochondrial fission 1 (FIS1) and displaced dynamin-related protein 1 (DRP1). Disruption of the fission machinery stabilized hyperfused mitochondria, thereby conferring lenvatinib resistance by suppressing drug-induced apoptosis and ROS generation. Both inhibiting lactate production and enforcing occupancy of the S148 site with substrates or a specific inhibitor blocked formation of the ABHD6–FIS1 complex, reactivated mitochondrial fission, and restored lenvatinib sensitivity. This study identified a lactate-driven functional switch in ABHD6 and established that targeting this allosteric mechanism is an effective therapeutic strategy to overcome lenvatinib resistance.Significance:Lactylated ABHD6 moonlights as a regulator of mitochondrial dynamics by sequestering FIS1 to drive lenvatinib resistance in hepatocellular carcinoma, which can be overcome by targeting ABHD6 to disrupt the non-canonical scaffolding function.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S8: Canonical ABHD6 substrates and WWL70 disrupt ABHD6-FIS1 interaction to reverse lenvatinib resistance and promote mitochondrial fragmentation.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S8: Canonical ABHD6 substrates and WWL70 disrupt ABHD6-FIS1 interaction to reverse lenvatinib resistance and promote mitochondrial fragmentation.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S7: Molecular and metabolic characterization of the ABHD6-FIS1 axis.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S7: Molecular and metabolic characterization of the ABHD6-FIS1 axis.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S9: In vivo validation of ABHD6-mediated drug resistance and immune evasion in orthotopic, HTVI, and syngeneic HCC models.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S9: In vivo validation of ABHD6-mediated drug resistance and immune evasion in orthotopic, HTVI, and syngeneic HCC models.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S5: Evaluation of ABHD6-mediated oncogenic functions and drug resistance
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma
Fig.S5: Evaluation of ABHD6-mediated oncogenic functions and drug resistance